6:16 AM ET
10-Q
Financial Results
Cognition Therapeutics Q3 2026 Results: Net Loss of $4.14M, Loss Narrows
Cognition Therapeutics reported a decrease in cash and cash equivalents to $30.8 million as of September 30, 2026, compared to $36.8 million at year-end 2025. The company's accumulated deficit grew to $211.3 million, reflecting ongoing clinical development costs for its lead product candidate, zervimesine (CT1812).
- Key figure
- Net loss $4.14M